Safety of recombinant human growth hormone

Endocrine Development

Volumn 18, Issue , 2010, Pages 40-54

  Carel, Jean Claude ^a   Butler, Gary ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C;

BRAIN PSEUDOTUMOR; CANCER RISK; CARCINOGENESIS; CHILD; DRUG SAFETY; GLUCOSE TOLERANCE; HUMAN; INCIDENCE; INSULIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OTITIS MEDIA; PRADER WILLI SYNDROME; PRIORITY JOURNAL; REVIEW; SCOLIOSIS; SIDE EFFECT; SLIPPED CAPITAL FEMORAL EPIPHYSIS; SUDDEN DEATH; TUMOR RECURRENCE;

CHILD; DRUG MONITORING; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; RECOMBINANT PROTEINS;

EID: 84864547253     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000316126     Document Type: Review

References (41)

1. Consensus: Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 2001; 86:1868-1870.
2. Cutfield WS, Wilton P, Bennmarker H, Albertsson- Wikland K, Chatelain P, Ranke MB, et al: Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 2000;355: 610-613.
3. Libman IM, Barinas-Mitchell E, Bartucci A, Robertson R, Arslanian S: Reproducibility of the oral glucose tolerance test in overweight children. J Clin Endocrinol Metab 2008;93:4231-4237.
4. Roman R, Zeitler PS: Oral glucose tolerance testing in asymptomatic obese children: more questions than answers. J Clin Endocrinol Metab 2008;93:4228-4230.
5. Malozowski S, Tanner LA, Wysowski DK, Fleming GA, Stadel BV: Benign intracranial hypertension in children with growth hormone deficiency treated with growth hormone. J Pediatr 1995;126: 996-999.
6. Quigley CA, Crowe BJ, Anglin DG, Chipman JJ: Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab 2002;87:2033-2041.
7. Stephure DK: Impact of growth hormone supplementation on adult height in Turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab 2005;90:3360-3366.
8. Davenport ML, Crowe BJ, Travers SH, Rubin K, Ross JL, Fechner PY, et al: Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial. J Clin Endocrinol Metab 2007;92: 3406-3416.
9. Eiholzer U: Deaths in children with Prader-Willi syndrome. A contribution to the debate about the safety of growth hormone treatment in children with PWS. Horm Res 2005;63:33-39.
10. Tauber M, Diene G, Molinas C, Hebert M: Review of 64 cases of death in children with Prader-Willi syndrome. Am J Med Genet A 2008;146:881-887.
11. Fillion M, Deal C, Van Vliet G: Retrospective study of the potential benefits and adverse events during growth hormone treatment in children with Prader-Willi syndrome. J Pediatr 2009;154: 230-233.
12. Tauber M, Hokken-Koelega AC, Hauffa BP, Goldstone AP: About the benefits of growth hormone treatment in children with Prader-Willi syndrome. J Pediatr 2009;154:778-779.
13. Stafler P, Wallis C: Prader-Willi syndrome: who can have growth hormone? Arch Dis Child 2008; 93:341-345.
14. Festen DA, de Lind van Wijngaarden R, van Eekelen M, Otten BJ, Wit JM, Duivenvoorden HJ, Hokken-Koelega AC: Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome. Clin Endocrinol 2008;69:443-451.
15. Cutfield W, Lundgren F: Insulin-like growth factor 1 and growth responses during the first year of growth hormone treatment in KIGS patients with idiopathic growth hormone deficiency, acquired growth hormone deficiency, turner syndrome and born small for gestational age. Horm Res 2009;71(suppl 1):39-45.
16. Quigley CA, Gill AM, Crowe BJ, Robling K, Chipman JJ, Rose SR, Ross JL, Cassorla FG, Wolka AM, Wit JM, Rekers-Mombarg LT, Cutler GB: Safety of growth hormone treatment in pediatric patients with idiopathic short stature. J Clin Endocrinol Metab 2005;90:5188-5196.
17. Bannink EM, van Doorn J, Mulder PG, Hokken- Koelega AC: Free/dissociable insulin-like growth factor (IGF)-1, not total IGF-1, correlates with growth response during growth hormone treatment in children born small for gestational age. J Clin Endocrinol Metab 2007;92:2992-3000.
18. Ranke MB, Traunecker R, Martin DD, Schweizer R, Schwarze CP, Wollmann HA, Binder G: IGF-1 and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age. Horm Res 2005; 64:68-76.
19. Phillip M, Lebenthal Y, Lebl J, Zuckerman-Levin N, Korpal-Szczyrska M, Marques JS, Steensberg A, Jons K, Kappelgaard AM, Ibanez L, European Norditropin SGASG: European multicentre study in children born small for gestational age with persistent short stature: comparison of continuous and discontinuous growth hormone treatment regimens. Horm Res 2009;71:52-59.
20. Jung H, Land C, Nicolay C, De Schepper J, Blum WF, Schonau E: Growth response to an individualised versus fixed dose GH treatment in short children born small for gestational age: the OPTIMA study. Eur J Endocrinol 2009;160:149-156.
21. Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG: Insulin growth factor- based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab 2007;92:2480-2486.
22. Hokken-Koelega AC, van Pareren YK, Arends N, Boonstra V: Efficacy and safety of long-term continuous growth hormone treatment of children born small for gestational age. Horm Res 2004; 62(suppl 3):149-154.
23. Bachmann S, Bechtold S, Bonfig W, Putzker S, Buckl M, Schwarz HP: Insulin sensitivity decreases in short children born small for gestational age treated with growth hormone. J Pediatr 2009; 154:509-513.
24. Cutfield WS, Regan FA, Jackson WE, Jefferies CA, Robinson EM, Harris M, Hofman PL: The endocrine consequences for very low birth weight premature infants. Growth Horm IGF Res 2004;14: S130-S135.
25. Hokken-Koelega A, van Pareren Y, Arends N, Boonstra V: Efficacy and safety of long-term continuous growth hormone treatment of children born small for gestational age. Horm Res 2004; 62(suppl 3):149-154.
26. Van Dijk M, Bannink EM, van Pareren YK, Mulder PG, Hokken-Koelega AC: Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormonetreated young adults born small for gestational age (SGA) and untreated short SGA controls. J Clin Endocrinol Metab 2007;92:160-165.
27. Simon D, Prieur AM, Quartier P, Charles Ruiz J, Czernichow P: Early recombinant Human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study. J Clin Endocrinol Metab 2007; 92:2567-2573.
28. Mencarelli F, Kiepe D, Leozappa G, Stringini G, Cappa M, Emma F: Growth hormone treatment started in the first year of life in infants with chronic renal failure. Pediatr Nephrol 2009;24: 1039-1046.
29. Radicioni AF, Paris, E, De Marco E, Anzuini A, Gandini L, Lenzi A: Testicular function in boys previously treated with recombinant human growth hormone for non-growth hormone-deficient short stature. J Endocrinol Invest 2007;30: 931-936.
30. Swerdlow AJ, Reddingius RE, Higgins CD, Spoudeas HA, Phipps K, Qiao Z, et al: Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab 2000;85:4444-4449.
31. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, et al: Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2002;87:3136-3141.
32. Jenkins PJ, Mukherjee A, Shalet SM: Does growth hormone cause cancer? Clin Endocrinol (Oxf) 2006;64:115-121.
33. Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, et al: Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006; 91:3494-3498.
34. Swerdlow AJ, Higgins CD, Adlard P, Preece MA: Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-1985: a cohort study. Lancet 2002;360:273-277.
35. Pollak MN, Schernhammer ES, Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-518.
36. Renehan AG, O'Connell J, O'Halloran D, Shanahan F, Potten CS, O'Dwyer ST, et al: Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Horm Metab Res 2003;35:712-725.
37. Orme SM, McNally RJ, Cartwright RA, Belchetz PE: Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83: 2730-2734.
38. Jenkins PJ, Frajese V, Jones AM, Camacho-Hubner C, Lowe DG, Fairclough PD, et al: Insulin-like growth factor 1 and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 2000;85:3218-3221.
39. Terzolo M, Reimondo G, Gasperi M, Cozzi R, Pivonello R, Vitale G, et al: Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. J Clin Endocrinol Metab 2005;90:84-90.
40. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M: Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-1353.
41. Safety and Appropriateness of Growth hormone treatments in Europe (SAGhE): http://saghe.aphp. fr/site/spip.php/